Holen Sie sich die Stockscreener-App
3.3591
1.37%
0.0691
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MannKind Corporation (MNKD) Options ChainYahoo Finance - ca.finance.yahoo.com
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - finance.yahoo.com
MannKind at H.C. Wainwright conference: new launches lift outlook - Investing.com
MannKind director Steven Binder sells $127,855 in company stock By Investing.com - Investing.com South Africa
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - Stock Titan
CT drugmaker partners on development of inhaled weight-loss treatment - Hartford Business Journal
MNKD Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesROE Trend Analysis - careplusvn.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind inks obesity deal with Rose Pharma - thepharmaletter.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - Yahoo Finance
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growt - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind to Present at Upcoming Investor Conferences - The Manila Times
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative - Yahoo Finance
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
MannKind (MNKD) Quarterly Update: Profit Per Share Falls Below Its Benchmark for This Review; Shares After the Report: The Stock Gains 4.36% in Latest TradingEarnings Expansion Phase - careplusvn.com
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
1.07%
1.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):